Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:physicist
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:multiple_endocrine_neoplasia_syndrome_type_2
|
| gptkbp:advocates_for |
gptkb:charity
awareness campaigns policy initiatives |
| gptkbp:associated_with |
gptkb:hemangioblastomas
gptkb:healthcare_organization gptkb:pheochromocytomas pancreatic tumors central nervous system tumors adrenal tumors retinal hemangioblastomas |
| gptkbp:caused_by |
tumors
|
| gptkbp:clinical_trial |
gptkb:stock_market_index
|
| gptkbp:current_use |
cysts
endolymphatic sac tumors |
| gptkbp:descendant |
autosomal dominant inheritance
|
| gptkbp:discovered_by |
Landmark von Hippel and Arvid Lindau
|
| gptkbp:first_described_by |
1894
|
| gptkbp:genetic_diversity |
gptkb:stock_market_index
recommended recommended for family members can identify mutations |
| https://www.w3.org/2000/01/rdf-schema#label |
Von Hippel-Lindau disease
|
| gptkbp:is_a_resource_for |
workshops
webinars brochures |
| gptkbp:is_involved_in |
local organizations
online communities medical conferences |
| gptkbp:is_popular_in |
1 in 36,000
|
| gptkbp:lifespan |
varies by individual
|
| gptkbp:manager |
multidisciplinary approach
|
| gptkbp:promoter |
gptkb:VHL_gene
|
| gptkbp:public_awareness |
patient advocacy groups
|
| gptkbp:research |
ongoing studies
|
| gptkbp:risk_factor |
family history
genetic mutations |
| gptkbp:screenings |
CT scans
ultrasound MRI scans |
| gptkbp:social_responsibility |
genetic testing
|
| gptkbp:subspecies |
3p25.3
|
| gptkbp:symptoms |
dizziness
fatigue nausea abdominal pain vision problems high blood pressure headaches tinnitus |
| gptkbp:treatment |
gptkb:hospital
gptkb:drug surveillance radiation therapy chemotherapy targeted therapy |